Literature DB >> 6587752

Verapamil and propranolol: a comparison of two antihypertensive agents.

G Leonetti, C Pasotti, G P Ferrari, A Zanchetti.   

Abstract

Verapamil, a calcium antagonist, was compared with propranolol, a widely used beta-adrenoreceptor blocker, in hypertensive patients with respect to its antihypertensive efficacy and incidence and severity of adverse effects. Both drugs caused similar blood pressure reductions without interfering with pulse pressure. The hypotensive effect of verapamil was not accompanied by any effect on heart rate, while after propranolol there was a significant bradycardia. ST-segment and T wave abnormalities at rest and after exercise were partially or completely reverted by both drugs. The incidence and severity of adverse effects was very low and no patient was withdrawn from the study because of complaints due to the active drugs. Verapamil can be compared as antihypertensive drug to the beta-blocker propranolol and this may justify, together with the absence of negative effects on lipids, blood sugar, serum electrolytes and renal function, its use as an antihypertensive drug of first choice.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6587752     DOI: 10.1111/j.0954-6820.1984.tb08688.x

Source DB:  PubMed          Journal:  Acta Med Scand Suppl        ISSN: 0365-463X


  4 in total

Review 1.  Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

2.  Effect of sustained-release verapamil therapy on the blood pressure at rest and on the pressor response to isometric exertion in hypertensive patients.

Authors:  C Cardillo; V Musumeci; L Savi; R Guardigli; N Mores; G Folli
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 3.  Calcium channel antagonists. Part III: Use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indications.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

4.  Hypertension therapy--an update.

Authors:  R B Cubberley
Journal:  J Natl Med Assoc       Date:  1987-11       Impact factor: 1.798

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.